The promise and perils of HDAC inhibitors in neurodegeneration.

ABSTRACT: Histone deacetylases (HDACs) represent emerging therapeutic targets in the context of neurodegeneration. Indeed, pharmacologic inhibition of HDACs activity in the nervous system has shown beneficial effects in several preclinical models of neurological disorders. However, the translation of such therapeutic approach to clinics has been only marginally successful, mainly due to our still limited knowledge about HDACs physiological role particularly in neurons. Here, we review the potential benefits along with the risks of targeting HDACs in light of what we currently know about HDAC activity in the brain.

SUBMITTER: Didonna A 

PROVIDER: S-EPMC4301678 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature